

# Anita Annahazi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6562455/publications.pdf>

Version: 2024-02-01

20  
papers

689  
citations

687363

13  
h-index

752698

20  
g-index

22  
all docs

22  
docs citations

22  
times ranked

1138  
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabotropic 5-HT receptor-mediated effects in the human submucous plexus. <i>Neurogastroenterology and Motility</i> , 2022, , e14380.	3.0	7
2	Region-specific effects of the cysteine protease papain on gastric motility. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14105.	3.0	4
3	From watery and fluffy to soft and formed: What shapes our stool?. <i>Journal of Physiology</i> , 2021, 599, 4521-4522.	2.9	0
4	The enteric nervous system: "A little brain in the gut". <i>Neuroforum</i> , 2020, 26, 31-42.	0.3	10
5	Anti-Hu antibodies activate enteric and sensory neurons. <i>Scientific Reports</i> , 2016, 6, 38216.	3.3	31
6	A pilot study on faecal MMP-9: a new noninvasive diagnostic marker of colorectal cancer. <i>British Journal of Cancer</i> , 2016, 114, 787-792.	6.4	38
7	Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-18.	1.5	15
8	The Diagnostic Value of a New Fecal Marker, Matrix Metalloprotease-9, in Different Types of Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 231-237.	1.3	44
9	Faecal matrix metalloprotease-9 is a more sensitive marker for diagnosing pouchitis than faecal calprotectin: results from a pilot study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 387-392.	3.0	9
10	Role of antispasmodics in the treatment of irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , 2014, 20, 6031.	3.3	80
11	Fecal MMP-9. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 316-320.	1.9	59
12	Luminal Cysteine-Proteases Degrade Colonic Tight Junction Structure and Are Responsible for Abdominal Pain in Constipation-Predominant IBS. <i>American Journal of Gastroenterology</i> , 2013, 108, 1322-1331.	0.4	69
13	Leaky Gut in Patients with Diarrhea-Predominant Irritable Bowel Syndrome and Inactive Ulcerative Colitis. <i>Digestion</i> , 2012, 85, 40-46.	2.3	68
14	"Ulcerative crepitus" A case with subcutaneous emphysema and pneumomediastinum without colonic perforation or toxic megacolon in ulcerative colitis successfully treated conservatively. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 717-719.	1.3	6
15	Intracolonic infusion of fecal supernatants from ulcerative colitis patients triggers altered permeability and inflammation in mice. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1409-1414.	1.9	20
16	Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice. <i>Pain</i> , 2009, 144, 209-217.	4.2	92
17	Luminal Cathepsin G and Protease-Activated Receptor 4. <i>American Journal of Pathology</i> , 2009, 175, 207-214.	3.8	63
18	Pre-treatment and post-treatment with Î±-tocopherol attenuates hippocampal neuronal damage in experimental cerebral hypoperfusion. <i>European Journal of Pharmacology</i> , 2007, 571, 120-128.	3.5	43

#	ARTICLE	IF	CITATIONS
19	Neuroprotection by Diazoxide in Animal Models for Cerebrovascular Disorders. <i>Vascular Disease Prevention</i> , 2006, 3, 253-263.	0.2	6
20	Diazoxide and dimethyl sulphoxide alleviate experimental cerebral hypoperfusion-induced white matter injury in the rat brain. <i>Neuroscience Letters</i> , 2005, 373, 195-199.	2.1	24